DMD and cardiomyopathy: Although further research is still required to comprehensively validate and characterize this model, the clear evidence of cardiomyopathy at 4 months of age (demonstrated by reduced left ventricular ejection fraction and fractioning shortening), paired with the close resemblance to its human DMD counterpart, makes this an attractive model for preclinical drug screening studies [82].